hydroxyurea

The initial treatment approach emphasized cytoreduction therapy with hydroxyurea, intravenous fluid administration, and preventive medication with allopurinol to protect against the risk of tumor lysis syndrome. After the patient became stabilized, imatinib, a first-line tyrosine kinase inhibitor, was started...As highlighted by this case, the importance of prompt diagnosis, the initiation of cytoreduction therapy, and the use of molecular therapy in treating CML in children cannot be neglected. CML in children is an uncommon but curable form of leukemia.

The patient was treated with phlebotomy, low-dose aspirin, and hydroxyurea, alongside continued vitamin B12 replacement. Close follow-up after hematologic recovery is essential to avoid delayed diagnosis of coexisting hematologic malignancies and disorders. This case presents a combination of complex and extremely rare hematological scenarios, where various hematological disorders exert conflicting influences on red blood cell indices, making diagnosis challenging.

No significant differences in TAS or TOS were observed between ELN (European LeukemiaNet) high-risk and low-risk patients, nor between those receiving hydroxyurea, aspirin, metformin, or ACE (angiotensin convertase enzyme) inhibitors and untreated patients (p > 0.05). Our findings demonstrate that oxidative stress is markedly elevated in patients with concomitant PV and MS, supporting a pathophysiological link between the two conditions. These results underscore the importance of considering oxidative stress in the clinical evaluation of PV patients with metabolic syndrome.

Initial treatment included hydroxyurea and dasatinib; however, after chronic-phase CML was confirmed, therapy was transitioned to imatinib, resulting in resolution of B symptoms, normalization of WBC counts, and reduced leg swelling. This case underscores the importance of distinguishing CEH from aggressive disease states, such as blast-phase CML or myeloid sarcoma, through comprehensive histopathological and immunohistochemical analysis.

P1, N=27, Recruiting, Bionoxx Inc. | Not yet recruiting --> Recruiting | Initiation date: Nov 2025 --> Mar 2026

The PROUD-CONTI study showed the superiority of rIFNα compared to hydroxyurea (HU), which led to the European Medicines Agency approval in 2019 of ropeginterferon alpha-2b ("ropegIFN") for ELN-defined high-risk PV patients. Moreover, as PV progresses, the development of myelofibrosis is the leading cause of morbidity, perhaps abetted by PHLEB-O. Here, we review recent progress in the treatment of PV with rIFNα and discuss our rationales and perspectives for, and the endorsement of the initial treatment with rIFNα of both low and high-risk PV patients, unless a contraindication exists to its use.

CHK1i+LDHU is a promising therapy for chemotherapy-resistant HGSOC, combining direct cytotoxic effects with reprogramming the TIME to reduce immunosuppression and activate a CD8+ T cell-dependent anti-tumour response.

P1, N=24, Not yet recruiting, Bionoxx Inc. | Initiation date: Dec 2025 --> Jan 2027

P2, N=17, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Mar 2026 --> Mar 2027 | Trial primary completion date: Mar 2026 --> Mar 2027

P2, N=50, Not yet recruiting, PETHEMA Foundation

Treatment with hydroxycarbamide and ruxolitinib resulted in decreased platelet counts and improved vasculitis, with no subsequent recurrence of cardiovascular events. This rare case shows that ruxolitinib can be effective in treating vasculitis complications in patients with JAK2 mutation-positive ET.

The patient received cytoreductive therapy with hydroxycarbamide, combined with dual antiplatelet therapy...Recently, JAK2 V617F mutation in vascular endothelial cells of patients with MPN has been documented, suggesting a potential association between MPN and arterial dissection or dissecting aneurysm. Although rare, such vascular complications can be life-threatening and should be recognized as clinically significant.